Showing 6,001 - 6,020 results of 7,701 for search '"Beijing"', query time: 0.06s Refine Results
  1. 6001
  2. 6002
  3. 6003
  4. 6004

    Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species by Zhang J, Li G, Hu J, Tan J, Zhang H, Zhou Y

    Published 2025-02-01
    “…Jinqing Zhang,1,* Gaolian Li,2,* Jing Hu,3,* Jingwen Tan,4 Heng Zhang,5 Yizheng Zhou5 1Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Gynaecology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei Province, People’s Republic of China; 3Department of Clinical Medicine, Xiangyang Polytechnic, Xiangyang, Hubei Province, People’s Republic of China; 4Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 5Department of Clinical Laboratory, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yizheng Zhou, Email zhou_yizheng@163.comIntroduction: Treating infections caused by azole-resistant Candida spp. poses a significant challenge. …”
    Get full text
    Article
  5. 6005
  6. 6006
  7. 6007
  8. 6008
  9. 6009
  10. 6010

    The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma by Wu Y, Zhu J, Zhang H, Xia N

    Published 2025-02-01
    “…Yintao Wu,* Jianyong Zhu,* Hong Zhang, Nianxin Xia Senior Department of Hepato-Pancreato-Biliary Surgery, the First Medical Center of PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Nianxin Xia, Senior Department of Hepato-Pancreato-Biliary Surgery, the First Medical Center of PLA General Hospital, Beijing, 100853, People’s Republic of China, Email doctorxnx@163.comPurpose: This study was developed to compare the efficacy of combined D-TACE-HAIC + lenvatinib + PD-1 inhibitor treatment to that of TACE + sorafenib treatment for patients with intermediate and advanced HCC.Patients and Methods: Here, a retrospective analysis of patients with unresectable HCC who underwent transarterial chemoembolization (TACE) from March 2018 to March 2022 at the our hospital was conducted. …”
    Get full text
    Article
  11. 6011
  12. 6012
  13. 6013
  14. 6014
  15. 6015
  16. 6016
  17. 6017
  18. 6018
  19. 6019
  20. 6020